EGFR and head and neck squamous cell carcinoma: The relevance of EGFR pathway in HNSCC led to the successful development of cetuximab in both the curative and palliative settings [8,9] and to the conduction of several trials with other antibodies directed against EGFR, such as panitumumab, zalutumumab and nimotuzumab [10-13], or RTK inhibitors involving downstream EGFR signaling [14, 15].